| Symbol | UNH |
|---|---|
| Name | UNITEDHEALTH GROUP INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Hospital & Medical Service Plans |
| Address | 1 HEALTH DRIVE, EDEN PRAIRIE, MN 55344 |
| Telephone | 1-800-328-5979 |
| Fax | — |
| — | |
| Website | https://www.unitedhealthgroup.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000731766 |
| Description | UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealths continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers. Additional info from NASDAQ: |
Conway Patrick Hugh 🔴 sold 1.2K shares of UNITEDHEALTH GROUP INC (UNH) at $390.00 Transaction Date: Aug 21, 2026 | Filing ID: 000201
Read more📋 Conway Patrick Hugh (Officer) plans to sell 1K shares of UNITEDHEALTH GROUP INC (at $390.00 each, total $456K) Filed: Aug 21, 2026 | ID: 006302
Read moreUnitedHealthcare Expands Access to Child and Family Behavioral Coaching to 13 Million Commercial Members
Read moreStankiewicz Dennis Andrew 🔴 sold 233 shares of UNITEDHEALTH GROUP INC (UNH) at $402.19 Transaction Date: Aug 11, 2026 | Filing ID: 000199
Read moreConway Patrick Hugh 🔴 sold 500 shares of UNITEDHEALTH GROUP INC (UNH) at $410.00 Transaction Date: Aug 05, 2026 | Filing ID: 000196
Read moreNew Form SCHEDULE 13G - UNITEDHEALTH GROUP INC <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000551 <b>Size:</b> 8 KB
Read more(10% Negative) UNITEDHEALTH GROUP INC (UNH) Reports Q3 2026 Financial Results
Read moreDirector Noseworthy John H 🟢 acquired 206 shares of UNITEDHEALTH GROUP INC (UNH) Transaction Date: Jul 01, 2026 | Filing ID: 000189
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07182838 | Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Thera… | Early_Phase1 | HIV Infections | Active_Not_Recruiting | 2025-09-12 | 2026-10-28 | ClinicalTrials.gov |
| NCT07145333 | Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Poly… | Phase2 | SCLC | Active_Not_Recruiting | 2025-08-12 | 2026-10-28 | ClinicalTrials.gov |
| NCT05245773 | MORE-PC: A 30-day Automated SMS Program to Support Post-discharge Transitions o… | Na | Care Transitions | Completed | 2022-03-29 | 2023-02-03 | ClinicalTrials.gov |
| NCT04663061 | Diabetes Data-Assisted Remission Trial (DDART) | Na | Type 2 Diabetes | Completed | 2021-06-09 | 2024-11-14 | ClinicalTrials.gov |
| NCT04810026 | Transform Type 2: Examining Meal-Delivery and Education for Diabetes Self-Care | Na | PreDiabetes | Completed | 2021-05-03 | 2021-10-26 | ClinicalTrials.gov |
| NCT04353037 | PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome… | Phase2 | Coronavirus | Terminated | 2020-04-07 | 2020-07-11 | ClinicalTrials.gov |
| NCT04327804 | A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Coll… | — | SARS-CoV Infection | Completed | 2020-03-25 | 2020-10-10 | ClinicalTrials.gov |
| NCT04321369 | Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Vi… | — | Infections, Respiratory | Completed | 2020-03-09 | 2020-03-23 | ClinicalTrials.gov |
| NCT03543176 | Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness | — | Pulmonary Disease, Chronic Obstructive | Completed | 2018-05-31 | 2019-08-21 | ClinicalTrials.gov |
| NCT03040310 | Personalized Back Rx Exercise Program as a Treatment for Discogenic Low Back Pa… | Na | Low Back Pain | Completed | 2016-01-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT02596204 | Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monit… | Na | Type 1 Diabetes Mellitus | Completed | 2015-09-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01649115 | The Healthy Lifestyles Passport Program: a Nutrition Education Program to Preve… | Na | Childhood Obesity | Unknown | 2012-08-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT03656991 | Bikes For Life: Measuring the Effects of a Bicycle Distribution Program on Pedi… | Na | Obesity, Childhood | Completed | 2012-04-06 | 2018-04-04 | ClinicalTrials.gov |
| NCT01757925 | Evaluation of a Commercial Gaming Impact in a Childhood Obesity Intervention | Phase4 | Childhood Obesity | Completed | 2011-08-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01374646 | Community-based Program to Treat Childhood Obesity | Na | Childhood Obesity | Completed | 2011-01-01 | 2012-06-05 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes | Other | Phase PHASE2 | Type 2 Diabetes | ACTIVE_NOT_RECRUITING | NCT07033585 |
| Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes | Other | Phase PHASE2 | Type 2 Diabetes | ACTIVE_NOT_RECRUITING | NCT07033585 |
| China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes | Other | Phase PHASE2 | Type 2 Diabetes | ACTIVE_NOT_RECRUITING | NCT07033585 |
| Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes | Other | Phase PHASE2 | Type 2 Diabetes | ACTIVE_NOT_RECRUITING | NCT07033585 |
| Healthy Lifestyles Passport | Other | Approved | Childhood Obesity | UNKNOWN | NCT01649115 |
| Healthy Lifestyles Passport | Other | Approved | Childhood Obesity | UNKNOWN | NCT01649115 |
| Active Gaming | Other | Phase PHASE4 | Childhood Obesity | COMPLETED | NCT01757925 |
| weight managment program | Other | Phase PHASE4 | Childhood Obesity | COMPLETED | NCT01757925 |
| FitBit | Other | Approved | Type 1 Diabetes Mellitus | COMPLETED | NCT02596204 |
| Weekly Review | Other | Approved | Type 1 Diabetes Mellitus | COMPLETED | NCT02596204 |
| Back Rx program | Other | Approved | Low Back Pain | COMPLETED | NCT03040310 |
| Bicycle intervention | Other | Approved | Obesity, Childhood | COMPLETED | NCT03656991 |
| Bicycle intervention | Other | Approved | Obesity, Childhood | COMPLETED | NCT03656991 |
| Diskus | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03543176 |
| Ellipta | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03543176 |
| mMRC | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03543176 |
| CAT | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03543176 |
| FLUT/SAL | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03543176 |
| UMEC/VI | Other | Preclinical | Pulmonary Disease, Chronic Obstructive | COMPLETED | NCT03543176 |
| JOIN Intervention | Other | Approved | Childhood Obesity | COMPLETED | NCT01374646 |
| Group 2 Placebo | Other | Phase PHASE2 | Coronavirus | TERMINATED | NCT04353037 |
| Group 1 HCQ | Other | Phase PHASE2 | Coronavirus | TERMINATED | NCT04353037 |
| Lifestyle coaching | Other | Approved | PreDiabetes | COMPLETED | NCT04810026 |
| Meal delivery | Other | Approved | PreDiabetes | COMPLETED | NCT04810026 |
| Education | Other | Approved | PreDiabetes | COMPLETED | NCT04810026 |
| Odd/Even birth year intervention groups | Other | Preclinical | SARS-CoV Infection | COMPLETED | NCT04327804 |
| Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals | Other | Preclinical | Infections, Respiratory | COMPLETED | NCT04321369 |
| Automated SMS program to support post-discharge transitions of care | Other | Approved | Care Transitions | COMPLETED | NCT05245773 |
| 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use | Other | Phase EARLY_PHASE1 | HPV Infection | ACTIVE_NOT_RECRUITING | NCT06959563 |
| 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use | Other | Phase EARLY_PHASE1 | HPV Infection | ACTIVE_NOT_RECRUITING | NCT06959563 |
| COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use | Other | Phase EARLY_PHASE1 | Covid19 | ACTIVE_NOT_RECRUITING | NCT03305341 |
| COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use | Other | Phase EARLY_PHASE1 | Covid19 | ACTIVE_NOT_RECRUITING | NCT03305341 |
| CEA protein antigen plus BCG Vaccine Mix for percutaneous use | Other | Phase PHASE1 | Rectal Cancer | ACTIVE_NOT_RECRUITING | NCT02403505 |
| CEA protein antigen plus BCG Vaccine Mix for percutaneous use | Other | Phase PHASE1 | Rectal Cancer | ACTIVE_NOT_RECRUITING | NCT02403505 |
| ETOPOSIDE - Study | Other | Phase PHASE2 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT01064466 |
| ETOPOSIDE - Usual | Other | Phase PHASE2 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT01064466 |
| ETOPOSIDE - Study | Other | Phase PHASE2 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT01064466 |
| ETOPOSIDE - Usual | Other | Phase PHASE2 | Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT01064466 |
| Topotecan - study | Other | Phase PHASE2 | SCLC | ACTIVE_NOT_RECRUITING | NCT07145333 |
| Topotecan - usual | Other | Phase PHASE2 | SCLC | ACTIVE_NOT_RECRUITING | NCT07145333 |
| Topotecan - study | Other | Phase PHASE2 | SCLC | ACTIVE_NOT_RECRUITING | NCT07145333 |
| Topotecan - usual | Other | Phase PHASE2 | SCLC | ACTIVE_NOT_RECRUITING | NCT07145333 |
| HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use | Other | Phase EARLY_PHASE1 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT07182838 |
| HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use | Other | Phase EARLY_PHASE1 | HIV Infections | ACTIVE_NOT_RECRUITING | NCT07182838 |
| Continuous glucose monitoring | Other | Approved | Type 2 Diabetes | COMPLETED | NCT04663061 |
| Diabetes education | Other | Approved | Type 2 Diabetes | COMPLETED | NCT04663061 |
| Medical weight loss | Other | Approved | Type 2 Diabetes | COMPLETED | NCT04663061 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Study | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |
| Alectinib - Usual | Other | Phase PHASE2 | Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05987956 |